Aleniglipron clinical trials
Also written GSBR-1290.
Its developmentBy Structure Therapeutics, step by step8 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses aleniglipron is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the aleniglipron studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (8)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test aleniglipron.
- Mar 2027Aleniglipron Renal Impairment StudyPhase 1 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Aug 2027Aleniglipron Hepatic Impairment StudyPhase 1 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Studies
Open first, then newest update. How each study uses aleniglipron is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Aleniglipron Renal Impairment StudyNot yet recruitingPhase 1Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07946068Written as AleniglipronHow we know
- Aleniglipron Hepatic Impairment StudyRecruitingPhase 1Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07872033Written as AleniglipronHow we know
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)RecruitingPhase 3Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07654374Written as aleniglipronHow we know
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)RecruitingPhase 3Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07654361Written as AleniglipronHow we know
- Aleniglipron Phase 2 in Type 2 Diabetes MellitusCompletedPhase 2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07400588Written as AleniglipronHow we know
- Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusCompletedPhase 1/2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT05762471Written as GSBR-1290How we know
- A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsActive, not recruitingPhase 1Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT06139055Written as GSBR-1290 (Capsule/Tablet)How we know
- A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy ParticipantsCompletedPhase 1Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT05893043Written as GSBR-1290How we know
As the comparator · 1 — what is tested is compared with aleniglipron
- A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityCompletedPhase 2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT06693843Written as AleniglipronHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Aleniglipron Hepatic Impairment StudyNov 17, 2026NCT07872033
Newly registered1
- Aleniglipron Renal Impairment StudyNov 18, 2026NCT07946068
Codes
What other systems call aleniglipron · ClinicalTrials.gg INT018660
- UNII (FDA) Z6XCL6R9SXALENIGLIPRONConfirmed FDA, Wikidata
- Wikidata Q123481209aleniglipronConfirmed FDA, Wikidata
- NCI Thesaurus C211832AleniglipronOne source FDA
- DrugBank DB18551One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z6XCL6R9SX | ALENIGLIPRON | Confirmed FDA, Wikidata |
| Wikidata | Q123481209 | aleniglipron | Confirmed FDA, Wikidata |
| NCI Thesaurus | C211832 | Aleniglipron | One source FDA |
| DrugBank | DB18551 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.